International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 3 , ISSUE 3 ( September-December, 2012 ) > List of Articles


Comparing the Efficacy of Urinary hCG vs Recombinant hCG for Final Maturation of Oocyte in GnRH Antagonist IVF/ICSI Cycle

MS Srinivas, G Ashwini Sidhmalswamy, K Dipika, K Anu, D Mekhala

Citation Information : Srinivas M, Sidhmalswamy GA, Dipika K, Anu K, Mekhala D. Comparing the Efficacy of Urinary hCG vs Recombinant hCG for Final Maturation of Oocyte in GnRH Antagonist IVF/ICSI Cycle. Int J Infertil Fetal Med 2012; 3 (3):92-96.

DOI: 10.5005/jp-journals-10016-1049

License: CC BY-NC 4.0

Published Online: 01-08-2015

Copyright Statement:  Copyright © 2012; The Author(s).


Aims and objectives

To compare the efficacy of urinary human chorionic gonadotropin (uhCG) vs recombinant human chorionic gonadotropin (rhCG) for triggering ovulation in gonadotropinreleasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycle.

Materials and methods

Two hundred patients who underwent GnRH antagonist IVF/ICSI cycles were analyzed, 100 of them received recombinant hCG 250 μg (injection overtrelle) and another group of 100 received urinary hCG (injection ovutrig) either 5000 IU or 10,000 IU for final oocyte maturation and ovulation trigger. The primary outcome measured was total oocytes retrieved and the secondary outcome measured 09 was the maturity rate fertilization rate, cleavage rate and clinical pregnancy rates were also compared.


Age, day 2 follicle stimulating hormone (FSH) and total dose of rFSH were comparable between the groups. There were no significant differences between the groups in terms of the mean number of oocytes retrieved per follicle (uhCG; 12.5, rhCG; 12.09, p-value-0.6698). Similarly, there was statistically no difference in any of the other parameters studied between the two groups. That is number of mature oocytes, number of fertilized oocytes and number of cleaved oocytes, as the p-value was not significant. The clinical pregnancy rate was somewhat higher in the uhCG group but was not statistically significant. Both treatments were well tolerated and there was no significant side effects for either drug.


There is no difference in clinical outcomes between urinary and recombinant hCG for induction of final oocyte maturation. Additional factors, including the cost, drug availability and ease of administration, should be considered, when choosing gonadotropin type.

How to cite this article

Sidhmalswamy GA, Srinivas MS, Dipika K, Anu K, Rao KA, Mekhala D. Comparing the Efficacy of Urinary hCG vs Recombinant hCG for Final Maturation of Oocyte in GnRH Antagonist IVF/ICSI Cycle. Int J Infertility Fetal Med 2012;3(3):92-96.

PDF Share
  1. Glycoprotein hormones (structure and function). Annu Rev Biochem 1981;50:465-95.
  2. Induction of ovulation with human gonadotropins. Recent Prog Horm Res 1965;21:179-204.
  3. The empty follicle syndrome: A pharmaceutical industry syndrome. Hum Repord 1996;10:2262-65.
  4. Recurrent empty follicle syndrome successfully treated with recombinant human chorionic gonadotropin. Hum Reprod 1999;14:1703-06.
  5. Stimulatioln of primate luteal function by recombinant human chorionic gonadotropin and modulation of steroid, but not relaxin, production by an inhibitor of 3 beta-hydroxysteroid dehydrogenase during simulated early pregnancy. J Clin Endocrinol Metab 1996;81:2307-13.
  6. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment— recombinant hCG versus urinary hCG. Human Reprod 2000;. Human Reprod 2000; 15(7):1446-51.
  7. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary hCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Human Reprod 2000;15(6):1305-10.
  8. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod 2005;20:1541-47.
  9. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. N Engl J Med 2006;35:1139-46.
  10. Hormonal dynamics at midcycle (a re-evaluation). J Clin Endocrinol Metab 1983;57:792-95.
  11. Clinical gynecologic endocrinology and infertility (6th ed). Baltimore: Lippincott Williams and Wilkins 1999:91-97.
  12. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: Results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization embryo transfer. Fertility Sterility 2001;76(1):67-74.
  13. Recombinant human luteinizing hormone is as effective as, but safer than urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: Results of a multicenter double-blind study. J Clin Endocrinol Metabol. J Clin Endocrinol Metabol 2001;86(6):2607-18.
  14. Recombinant hCG for triggering ovulation increases the rate of mature oocytes in women treated for ICSI. J Assist Reprod Genetics 2008; 25(9-10):461-66.
  15. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization. Fertility Sterility 2008;90(6):2133-37.
  16. Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in singleblastocyst IVF antagonist cycles: A randomized controlled trial. Fertility Sterility 2010;94(7):2902-04.
  17. Endometrial advancement after triggering with recombinant or urinary HCG: A randomized controlled pilot study. Reprod Biomed Online 2010;21(1):50-55.
  18. Histologic and functional aspects of the endometrium in the implantatory phase. Gynecol Obstet Invest 2007;64:131-33.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.